Molecular Detection Inc.
Definitively diagnosing MRSA
This article was originally published in Start Up
Methicillin-resistant staphylococcus aureus infections are deadly for patients and expensive for hospitals to treat. Current methods of detecting MRSA are plagued with significant numbers of false-positive results. Molecular Detection Inc.’s Detect-Ready screening assay is designed to distinguish accurately if a positive result indicates the presence of MRSA or a combination of different bacteria, some of which may not be resistant to antibiotics. The test can be run with equipment found in most clinical laboratories, enabling hospitals to make informed clinical decisions about the best way to treat patients.
You may also be interested in...
COVID-test maker Cue Health said it laid off 170 people in its manufacturing facility but remains “confident in its long-term strategy.”
Roivant and Pfizer launched Priovant to develop the oral drug brepocitinib for dermatomyositis, lupus and other autoimmune diseases, but Roivant also cut programs to extend its cash runway.
HHS will take steps to increase access to abortion medication and prevent states from banning it, Secretary Becerra says, but also is questioned about whether the FDA can speed up certification of pharmacies and if the Justice Department would sue states banning access.